News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ddssf is hitting solid today.
hi my friend. true very true; ddssf
yellow, 1-yr.,ema8 , ema34, bb, volume, price, cloud
white, / 1yr. , 50ma , 200ma, r.s.i., volume, macd
blue/white / 18-mos, ma50, ma200, ema20, cloud, volume, r.s.i., macd, price
gray / 5-MOS , 50ma , 200ma , bb , r.s.i. , macd , full sto , volume , price
low Float Stock Plays / chart;
BLACK, 6 MOS, R.S.I. , 50MA , 200MA , VOLUME , MACD , PPO
3 mos, ma50, bb, sar, volume, pps, cci, macd, trix
3 mos, ma50, bb, sar, volume, pps,accum./dist.,adx, atr
|
Followers
|
24
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1202
|
|
Created
|
06/01/07
|
Type
|
Free
|
| Moderators | |||
Board of Directors
Santo J. Costa 3
Mark D'Souza
Julia Brown 1
Richard J. MacKay 3
Frédéric Porte 2
Jacques Roy 1,2
Rachel R. Selisker 1,2
Officers
Mark D'Souza
President and CEO
Damon Smith
Senior Vice-President, Research and Development
Gregory M.C. Orleski
Vice-President, Business Development
Jeffrey M. Dayno, M.D.
Chief Medical Officer
Sylvain Guénette, CA
Chief Financial Officer
Sybil Skinner-Robertson
Vice-president, Regulatory Affairs
Labopharm, Inc.
(Head Office)
480 Armand-Frappier Blvd.
Laval, Quebec, H7V 4B4
Canada
Tel: (450) 686-0207
Fax: (450) 686-9141
Labopharm USA, Inc.
202 Carnegie Center,
Suite 204
Princeton, NJ 08540
United States
Tel: (609) 454-0207
Fax: (609) 454-0202
Labopharm Europe Limited
5, The Seapoint Building
44 Clontarf Road
Dublin 3, Ireland
Tel:+353 (0)1 854 0140
Fax:+353 (0)1 854 0144
Labopharm, Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies. It offers a once-daily formulation of the pain-killer, tramadol to treat patients with moderate to severe pain in the United States, Europe, Mexico, Latin America, and the Caribbean. The company conducts Phase III clinical studies for once-daily formulations of Trazodone, an antidepressant; Phase I clinical studies for Tramadol combination products to meter the dispersion of two active ingredients for clinically beneficial interaction between the drugs;
Phase I clinical studies for abuse resistant formulations of an opioid drug to provide patient safety; and Phase I clinical studies for anti-inflammatory products. It also develops a once-daily formulation of betahistine, an oral histamine analogue, for the treatment of the symptoms related to Meniere's disease, a disorder characterized by recurrent vertigo and hearing loss; and DDS-2001, an undisclosed formulation in Phase I studies. Labopharm's products are based on Contramid platform, a drug delivery technology that meters the release of drugs from orally administered solid dosage forms, such as tablets. In addition, it develops polymeric nano-delivery systems for delivery of water-insoluble and poorly bio-available drugs, as well as for developing intravenous and oral formulation product candidates. The company was founded in 1990. It was formerly known as Centre de recherche appliquee pharmaceutique CRAP, inc. and changed its name to Labopharm, Inc. in 1994. Labopharm, Inc. is headquartered in Laval, Canada.
overview
http://finance.yahoo.com/q/ks?s=DDSSF.PK+Key+Statistics
Shares Outstanding5: 71.57M
Float: 71.11M
| 6-K | Jul 12, 2011 | Jul 12, 2011 | 10.6 KB |  PDF  RTF  HTML |
| 15-12G | Jul 12, 2011 | 10.3 KB | PDF RTF HTML  XLS |
FORM 6-K
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8038056
http://rttnews.com/ArticleView.aspx?Id=1184469&pageNum=2978_5599_8156_8314_1
